BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 22370315)

  • 21. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
    N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.
    Schagen SB; van Dam FS; Muller MJ; Boogerd W; Lindeboom J; Bruning PF
    Cancer; 1999 Feb; 85(3):640-50. PubMed ID: 10091737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer.
    Kreukels BP; van Dam FS; Ridderinkhof KR; Boogerd W; Schagen SB
    Clin Breast Cancer; 2008 Feb; 8(1):80-7. PubMed ID: 18501062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer.
    Nolan L; Darby A; Boleti K; Simmonds P
    Breast; 2011 Apr; 20(2):151-4. PubMed ID: 20970333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
    Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
    Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
    Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
    Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.
    Hurria A; Rosen C; Hudis C; Zuckerman E; Panageas KS; Lachs MS; Witmer M; van Gorp WG; Fornier M; D'Andrea G; Moasser M; Dang C; Van Poznak C; Hurria A; Holland J
    J Am Geriatr Soc; 2006 Jun; 54(6):925-31. PubMed ID: 16776787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive deficits in Korean women treated with chemotherapy for breast cancer.
    Jung MS; Cimprich B
    Cancer Nurs; 2014; 37(3):E31-42. PubMed ID: 23945143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors.
    Breckenridge LM; Bruns GL; Todd BL; Feuerstein M
    Psychooncology; 2012 Jan; 21(1):43-53. PubMed ID: 20967847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of memory deficits following chemotherapy in breast cancer survivors: evidence from the doors and people test.
    Prokasheva S; Faran Y; Cwikel J; Geffen DB
    J Psychosoc Oncol; 2011; 29(5):499-514. PubMed ID: 21882931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study.
    Kreukels BP; Schagen SB; Ridderinkhof KR; Boogerd W; Hamburger HL; Muller MJ; van Dam FS
    Clin Breast Cancer; 2006 Apr; 7(1):67-78. PubMed ID: 16764746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.